{"id":"W3170399786","doi":"10.1200/jco.2021.39.15_suppl.tps7572","title":"ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; Internal medicine; Population; Diffuse large B-cell lymphoma; CHOP; Gastroenterology; Rituximab; Vincristine; Phases of clinical research; Ibrutinib; Oncology; Cyclophosphamide; Surgery; Lymphoma; Chronic lymphocytic leukemia; Clinical trial; Leukemia; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001227724,0.001563419,0.001906793,0.0006106322,0.0004013465,0.001440426,0.001157604,0.001254848,0.005881108],"category_scores_gemma":[0.0007207171,0.0006251042,0.001689255,0.0005269254,0.0008169354,0.001164068,0.0005465496,0.004050171,0.001483305],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009052641,"about_ca_system_score_gemma":0.001065774,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001667368,"about_ca_topic_score_gemma":0.003847031,"domain_scores_codex":[0.9996231,0.000158715,0.00001560448,0.00006139509,0.00004805771,0.0000932262],"domain_scores_gemma":[0.9995302,0.00006470953,0.00008095474,0.00004423045,0.00003148389,0.0002485308],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6478108,0.1399129,0.005277234,0.001411128,0.002211236,0.0003278894,0.0006635757,0.003536977,0.04562822,0.0006277338,0.006364716,0.1462276],"study_design_scores_gemma":[0.7355442,0.2472391,0.009568789,0.00005171883,0.0004525481,0.0002692385,0.00008734768,0.001339214,0.001762238,0.0003250793,0.003327857,0.00003264505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902999,0.002209906,0.0005296279,0.0004663346,0.000135585,0.002381705,0.001191067,0.0002130031,0.002572764],"genre_scores_gemma":[0.9829957,0.003395465,0.002255935,0.001333335,0.0002090968,0.003531259,0.002886154,0.00007610386,0.00331709],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005881108,"threshold_uncertainty_score":0.01967424,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02757369438118631,"score_gpt":0.3926581560045246,"score_spread":0.3650844616233383,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}